NetworkNewsBreaks Archive - Page 2141 of 2221

ThursdayApr 20, 2017 9:45 am

NetworkNewsBreaks – MGX Minerals, Inc. (MGXMF) Announces Results from Independent Testing of Proprietary Lithium Extraction Process

Diversified mining company MGX Minerals, Inc. (OTC: MGXMF) this morning announced that it has received independent laboratory-testing results from the Saskatchewan Research Council (“SRC”) regarding its patent-pending “Method for Extraction of Lithium from Salt Brine” (U.S. Provisional Patent #62/419,011). The results from the SRC noted that MGX’s proprietary extraction process was successful in recovering up to 83.7% lithium and concentrating 461 ppm lithium from a 71 ppm representative sample of formation brine originating from the Sturgeon Lake oilfield. “The results of laboratory testing by SRC provide third-party validation of our proprietary design process and its ability to rapidly separate lithium…

WednesdayApr 19, 2017 12:37 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on April 19, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: HDYN 22.95% – News: Signs third amendment to production sharing contract with SAPETRO and the Republic of Guinea; Names new senior VP and CFO CYTR 15.48% – News: Reaches agreement with FDA on aldoxorubicin NDA to treat STS HIPC 8.79% – News: Completes second round of financing WSTL 5.13% – News: Selected to support 2017 New York City subway project by Transit Wireless VPRB 4.74% – News: Launches new online retail portal, opens new…

WednesdayApr 19, 2017 11:15 am

NetworkNewsBreaks – Marathon Patent Group, Inc. (NASDAQ: MARA) Prices $2.66M Synchronized Registered Direct Offering and Private Placement

Marathon Patent Group (NASDAQ: MARA) recently entered into definitive agreements with investors for the purchase and sale of 3,800,000 shares of common stock at a price of $0.70 per share in a registered direct offering, as well as warrants to purchase up to 2,280,000 shares of common stock at an effective price of $0.01 per warrant with an exercise price of $0.83 per share in a concurrent private placement. Gross proceeds of the offerings are expected to be approximately $2,660,000 before fees, expenses and placement agent discounts. The company plans to use the net proceeds for working capital and other…

WednesdayApr 19, 2017 9:22 am

NetworkNewsBreaks – National Waste Management Holdings, Inc. (NWMH) Records Triple-Digit Revenue Growth in 2016

Emerging vertically integrated solid waste management company National Waste Management Holdings, Inc. (OTC: NWMH) this morning announced its financial results for the full year ended December 31, 2016. Among the highlights, the company’s revenues for the 12-month period totaled $6.3 million, marking a year-over-year increase of 161 percent. This strong revenue growth was fueled by NWMH’s aggressive acquisition-based growth strategy, which led to the acquisitions of both Northeast Data and Recycling, LLC and Sivart Services, LLC during the year ended December 31, 2016. “We executed a number of achievements throughout 2016, and are pleased to report the positive impacts of…

WednesdayApr 19, 2017 8:57 am

NetworkNewsBreaks – Ocera Therapeutics, Inc. (NASDAQ: OCRX) Reiterated with ‘Buy’ Rating, $3 PT at Aegis Capital

Aegis Capital Corp. has reiterated its ‘Buy’ rating and $3 price target on Ocera Therapeutics (NASDAQ: OCRX) following the company’s recent release of data from a preclinical model that suggests potential for OCR-002 as a treatment of Non-alcoholic Fatty Liver Disease (NAFLD)/ Non-alcoholic Steatohepatitis (NASH). The analyst noted this data, and OCR-002's potential as a treatment of Hepatic Encephalopathy (HE), as the sole reason for the reiterated ‘Buy’ rating. For more information, visit www.ocerainc.com About Ocera Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations.…

WednesdayApr 19, 2017 8:55 am

NetworkNewsBreaks – ViewRay, Inc. (NASDAQ: VRAY) Receives ‘Buy’ Rating, $11 PT at Aegis Capital

Aegis Capital Corp. recently issued a ‘Buy’ rating and price target of $11 on shares of ViewRay, Inc. (NASDAQ: VRAY). The action follows ViewRay’s recent agreement with CRG LP to amend the terms of its $50 million term loan agreement to expand the borrowing capacity to $65 million. The analyst noted this extension, as well as the company’s preliminary first-quarter results, which included two orders for the LINAC with gross proceeds of $12.3 million and three upgrades to installed Cobalt machines to LINACs for $5.8 million. The LINAC was approved in late February, and the analyst cited this as a major inflection point…

TuesdayApr 18, 2017 1:05 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on April 18, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: KWBT 50.00% – News: Posts Q4, FY 2016 results RBNW 15.21% – News: Opens distribution center in Hayward, California VPRB 13.89% – News: Posts Q4, FY 2016 results MYSZ 13.08% – News: Signs cooperation agreement with the Israeli Postal Service FTLF 8.93% – News: Posts Q4, FY 2016 results MDCL 8.07% – News: Files 2016 annual report, issues Q1 2017 guidance CATB 6.12% – News: Presenting at the American Academy of Neurology 69th Annual…

TuesdayApr 18, 2017 1:05 pm

NetworkNewsBreaks – Trevena, Inc. (NASDAQ: TRVN) Reiterated with ‘Buy’ Rating, $14 PT at Aegis Capital

Trevena, Inc. (NASDAQ: TRVN) has been reiterated with a ‘Buy’ rating and $14 price target at Aegis Capital Corp., which noted that the commercial potential of the company’s Olinvo is “under-appreciated.” Olinvo differs from existing active drugs indicated for post-operative pain management by its mechanism of action, and it could be the first in a new class of molecules to receive FDA approval. The Aegis analyst noted that phase 3 read-outs demonstrated efficacy near the equivalent of morphine, as well as with improved side effect profiles, especially for respiratory depression and GI side effects. Aegis also estimated that Olinvo could generate…

TuesdayApr 18, 2017 12:21 pm

NetworkNewsBreaks – Biocept, Inc. (NASDAQ: BIOC) Expands IP with Japanese Patent for Target Selector™ Liquid Biopsy Platform

Biocept (NASDAQ: BIOC) this morning said it has been awarded a Japanese patent covering the use of antibodies for the capture of any target of interest from any sample type on a device surface including circulating tumor cells (CTCs). The patent, entitled “Devices And Methods Of Cell Capture And Analysis,” is broader than previously issued patents owned by the company and is the 19th patent issued to Biocept related to its core liquid biopsy technology. "This is our third patent issued in Japan, strengthening the protection of our proprietary liquid biopsy technology in an important healthcare market. Expanding our intellectual…

TuesdayApr 18, 2017 12:18 pm

NetworkNewsBreaks – Interpace Diagnostics Group, Inc. (NASDAQ: IDXG): UnitedHealthcare Agrees to Cover ThyraMIR®; Shares Skyrocket

Interpace Diagnostics Group (NASDAQ: IDXG) shares are up 95% in late morning trade after the company said that UnitedHealthcare, the largest health plan in the United States, has agreed to cover its ThyraMIR® test used in assessing indeterminate thyroid nodule fine needle aspirate (FNA) biopsies. The coverage is now in effect and is subject to members' specific benefit plan design. Including the new coverage with UnitedHealthcare, Interpace's ThyGenX® and ThyraMIR assays are now covered for approximately 250 million patients nationwide. To view the full press release, visit: http://nnw.fm/CFDp7 About Interpace Diagnostics Group, Inc. Interpace is a fully integrated commercial company…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks